---
schema_version: "secwatch.filing_event.v1"
accession: "0000010795-24-000015"
form_type: "8-K"
ticker: "BDX"
cik: "0000010795"
company_name: "BECTON DICKINSON & CO"
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T10:34:58.346693+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BD Q1 revenue $4.7B (+2.6% YoY), GAAP EPS $0.96, adj. EPS $2.68; raises FY2024 guide

## Summary
- Q1 revenue $4,706M, up 2.6% as reported, 2.4% organic; currency-neutral growth 1.6%.
- GAAP diluted EPS $0.96 vs. $1.70 prior year; adjusted diluted EPS $2.68 vs. $2.98.
- Company raises full-year adjusted EPS guidance and midpoint of organic revenue growth guidance.
- BD Medical launched SiteRite 9 Ultrasound System; BD Life Sciences received FDA clearance for MiniDraw Capillary Blood Collection System.
- BD signed World Economic Forum's Zero Health Gaps Pledge, reinforcing health equity commitment.

## SEC filing metadata
- accession: 0000010795-24-000015
- form_type: 8-K
- ticker: BDX
- cik: 0000010795
- company_name: BECTON DICKINSON & CO
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10795/000001079524000015/0000010795-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10795/000001079524000015/bdx-20240201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000010795-24-000015
- JSON: https://secwatch.observer/filing/0000010795-24-000015.json
- Plain text: https://secwatch.observer/filing/0000010795-24-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.